Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities

Area of Science:

• Neuroscience
• Pharmacology
• Addiction Medicine

Background:

• Psychotropic drugs generally fail to improve alcohol abstinence rates in non-comorbid patients.
• Alcohol's effects on neurotransmitter systems, including glutamate, dopamine, and serotonin, are key to its reinforcing properties and craving.
• Neurobiological findings guide the development of pharmacological treatments for alcoholism.

Purpose of the Study:

• To review pharmacological agents for reducing alcohol relapse.
• To evaluate the efficacy of existing and potential anti-craving medications.

Main Methods:

• Review of published studies on the neurobiology of alcohol dependence.
• Analysis of clinical trial data for pharmacological interventions.
• Assessment of drugs targeting neurotransmitter systems involved in alcohol reinforcement.

Main Results:

• Acamprosate and opioid antagonists (naltrexone, nalmefene) demonstrate the most promise for reducing alcohol craving.
• Acamprosate and naltrexone are established first-choice treatments in many regions.
• Selective serotonin reuptake inhibitors may benefit patients with comorbid depression or cognitive deficits, but generally do not improve abstinence rates.

Conclusions:

• Acamprosate and naltrexone are leading pharmacological options for alcohol relapse prevention.
• Further research is needed for other agents like buspirone, ondansetron, and dopaminergic drugs.
• Targeting specific neurotransmitter systems offers a promising avenue for alcoholism treatment.